FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007118857> ?p ?o ?g. }

• W2007118857 endingPage "161" @default.
• W2007118857 startingPage "160" @default.
• W2007118857 abstract "OBJECTIVE: To evaluate the pharmacoeconomics of mitoxantrone (m) therapy in patients with progressive-relapsing and secondary-progressive multiple sclerosis (MS). METHODS: The MIMS trial showed that m improves several outcomes in patients with progressive-relapsing and secondary-progressive multiple sclerosis (MS). Patients receiving m 12 mg/m2 every three months had fewer relapses and hospitalizations, less progression of neurologic disability, and improved quality of life and functionality. A pharmacoeconomic analysis was undertaken to compare resource consumption in the m and placebo (p) groups. Major cost drivers were identified as follows: drug therapy, including acquisition, administration, and monitoring (primarily m, IV corticosteroids, and antibiotics); hospitalizations (5 days/occurrence); physician visits (1/relapse); days lost from work (2/documented relapse, 3 additional for relapse requiring IV corticosteroids, and 7/hospitalization). Standard costs were assigned as follows: m ($1000/cycle); IV corticosteroids used to treat relapses ($1250/occurrence); antibiotics used to treat infections ($300/occurrence); hospitalizations ($1850/day); physician visits ($100/occurrence); wages ($160/day). RESULTS: A cost-minimization analysis was done and the cost per patient per year was found to be as follows: m therapy (m = $4000, p = $0); IV corticosteroid therapy (m = $250, p = $750); antibiotic therapy (m = $96, p = $39); hospitalization (m = $1850, p = $3145); physician visits (m = $40, p = $100); lost wages (m = $448, p = $989). The total annual cost per patient was $6684 in the m group and $5023 in the p group. The annual cost of m ($4000) was substantially offset by a reduction in other costs associated with p for a total annual incremental m cost of $1661. CONCLUSIONS: MS is a chronic, debilitating disease associated with considerable costs. Pharmacoeconomic analyses suggest that m compares favorably with other disease-modifying therapies for MS. Additional data will be presented using remaining direct and indirect cost drivers. The results of cost-effectiveness analyses incorporating patient outcome measures will also be presented." @default.
• W2007118857 created "2016-06-24" @default.
• W2007118857 creator A5028729197 @default.
• W2007118857 creator A5030683943 @default.
• W2007118857 creator A5070899785 @default.
• W2007118857 creator A5089743528 @default.
• W2007118857 date "2001-09-01" @default.
• W2007118857 modified "2023-09-30" @default.
• W2007118857 title "PPN20: ESTIMATED RESOURCE USE AND COST OF MITOXANTRONE VS PLACEBO IN PATIENTS WITH PROGRESSIVE-RELAPSING AND SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS: RESULTS FROM THE MIMS TRIAL" @default.
• W2007118857 doi "https://doi.org/10.1046/j.1524-4733.2001.40202-242.x" @default.
• W2007118857 hasPublicationYear "2001" @default.
• W2007118857 type Work @default.
• W2007118857 sameAs 2007118857 @default.
• W2007118857 citedByCount "1" @default.
• W2007118857 countsByYear W20071188572021 @default.
• W2007118857 crossrefType "journal-article" @default.
• W2007118857 hasAuthorship W2007118857A5028729197 @default.
• W2007118857 hasAuthorship W2007118857A5030683943 @default.
• W2007118857 hasAuthorship W2007118857A5070899785 @default.
• W2007118857 hasAuthorship W2007118857A5089743528 @default.
• W2007118857 hasBestOaLocation W20071188571 @default.
• W2007118857 hasConcept C126322002 @default.
• W2007118857 hasConcept C142724271 @default.
• W2007118857 hasConcept C143998085 @default.
• W2007118857 hasConcept C203014093 @default.
• W2007118857 hasConcept C204787440 @default.
• W2007118857 hasConcept C27081682 @default.
• W2007118857 hasConcept C2776694085 @default.
• W2007118857 hasConcept C2780640218 @default.
• W2007118857 hasConcept C2780923524 @default.
• W2007118857 hasConcept C71924100 @default.
• W2007118857 hasConceptScore W2007118857C126322002 @default.
• W2007118857 hasConceptScore W2007118857C142724271 @default.
• W2007118857 hasConceptScore W2007118857C143998085 @default.
• W2007118857 hasConceptScore W2007118857C203014093 @default.
• W2007118857 hasConceptScore W2007118857C204787440 @default.
• W2007118857 hasConceptScore W2007118857C27081682 @default.
• W2007118857 hasConceptScore W2007118857C2776694085 @default.
• W2007118857 hasConceptScore W2007118857C2780640218 @default.
• W2007118857 hasConceptScore W2007118857C2780923524 @default.
• W2007118857 hasConceptScore W2007118857C71924100 @default.
• W2007118857 hasIssue "2" @default.
• W2007118857 hasLocation W20071188571 @default.
• W2007118857 hasOpenAccess W2007118857 @default.
• W2007118857 hasPrimaryLocation W20071188571 @default.
• W2007118857 hasRelatedWork W1215616443 @default.
• W2007118857 hasRelatedWork W1666527189 @default.
• W2007118857 hasRelatedWork W1989019271 @default.
• W2007118857 hasRelatedWork W2018320049 @default.
• W2007118857 hasRelatedWork W2053339951 @default.
• W2007118857 hasRelatedWork W2090970329 @default.
• W2007118857 hasRelatedWork W2144633544 @default.
• W2007118857 hasRelatedWork W2413968406 @default.
• W2007118857 hasRelatedWork W2617222556 @default.
• W2007118857 hasRelatedWork W3037339384 @default.
• W2007118857 hasVolume "4" @default.
• W2007118857 isParatext "false" @default.
• W2007118857 isRetracted "false" @default.
• W2007118857 magId "2007118857" @default.
• W2007118857 workType "article" @default.